Cargando…
Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study
BACKGROUND: In human immunodeficiency virus treatment adequate virological suppression is warranted, nevertheless for some patients it remains a challenge. We investigated factors associated with low-level viraemia (LLV) and virological failure (VF) under combined antiretroviral therapy (cART). MATE...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643888/ https://www.ncbi.nlm.nih.gov/pubmed/26566025 http://dx.doi.org/10.1371/journal.pone.0142923 |
_version_ | 1782400580223762432 |
---|---|
author | Leierer, Gisela Grabmeier-Pfistershammer, Katharina Steuer, Andrea Geit, Maria Sarcletti, Mario Haas, Bernhard Kanatschnig, Manfred Rappold, Michaela Zangerle, Robert Ledergerber, Bruno Taylor, Ninon |
author_facet | Leierer, Gisela Grabmeier-Pfistershammer, Katharina Steuer, Andrea Geit, Maria Sarcletti, Mario Haas, Bernhard Kanatschnig, Manfred Rappold, Michaela Zangerle, Robert Ledergerber, Bruno Taylor, Ninon |
author_sort | Leierer, Gisela |
collection | PubMed |
description | BACKGROUND: In human immunodeficiency virus treatment adequate virological suppression is warranted, nevertheless for some patients it remains a challenge. We investigated factors associated with low-level viraemia (LLV) and virological failure (VF) under combined antiretroviral therapy (cART). MATERIALS AND METHODS: We analysed patients receiving standard regimens between 1(st) July 2012 and 1(st) July 2013 with at least one viral load (VL) measurement below the quantification limit (BLQ) in their treatment history. After a minimum of 6 months of unmodified cART, the next single VL measurement within 6 months was analysed. VF was defined as HIV RNA levels ≥200 copies/mL and all other quantifiable measurements were classified as LLV. Factors associated with LLV and VF compared to BLQ were identified by logistic regression models. RESULTS: Of 2276 participants, 1972 (86.6%) were BLQ, 222 (9.8%) showed LLV and 82 (3.6%) had VF. A higher risk for LLV and VF was shown in patients with cART interruptions and in patients with boosted PI therapy. The risk for LLV and VF was lower in patients from centres using the Abbott compared to the Roche assay to measure VL. A higher risk for LLV but not for VF was found in patients with a higher VL before cART [for >99.999 copies/mL: aOR (95% CI): 4.19 (2.07–8.49); for 10.000–99.999 copies/mL: aOR (95% CI): 2.52 (1.23–5.19)] and shorter cART duration [for <9 months: aOR (95% CI): 2.59 (1.38–4.86)]. A higher risk for VF but not for LLV was found in younger patients [for <30 years: aOR (95% CI): 2.76 (1.03–7.35); for 30–50 years: aOR (95% CI): 2.70 (1.26–5.79)], people originating from high prevalence countries [aOR (95% CI): 2.20 (1.09–4.42)] and in male injecting drug users [aOR (95% CI): 2.72 (1.38–5.34)]. CONCLUSIONS: For both VF and LLV, factors associated with adherence play a prominent role. Furthermore, performance characteristics of the diagnostic assay used for VL quantification should also be taken into consideration. |
format | Online Article Text |
id | pubmed-4643888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-46438882015-11-18 Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study Leierer, Gisela Grabmeier-Pfistershammer, Katharina Steuer, Andrea Geit, Maria Sarcletti, Mario Haas, Bernhard Kanatschnig, Manfred Rappold, Michaela Zangerle, Robert Ledergerber, Bruno Taylor, Ninon PLoS One Research Article BACKGROUND: In human immunodeficiency virus treatment adequate virological suppression is warranted, nevertheless for some patients it remains a challenge. We investigated factors associated with low-level viraemia (LLV) and virological failure (VF) under combined antiretroviral therapy (cART). MATERIALS AND METHODS: We analysed patients receiving standard regimens between 1(st) July 2012 and 1(st) July 2013 with at least one viral load (VL) measurement below the quantification limit (BLQ) in their treatment history. After a minimum of 6 months of unmodified cART, the next single VL measurement within 6 months was analysed. VF was defined as HIV RNA levels ≥200 copies/mL and all other quantifiable measurements were classified as LLV. Factors associated with LLV and VF compared to BLQ were identified by logistic regression models. RESULTS: Of 2276 participants, 1972 (86.6%) were BLQ, 222 (9.8%) showed LLV and 82 (3.6%) had VF. A higher risk for LLV and VF was shown in patients with cART interruptions and in patients with boosted PI therapy. The risk for LLV and VF was lower in patients from centres using the Abbott compared to the Roche assay to measure VL. A higher risk for LLV but not for VF was found in patients with a higher VL before cART [for >99.999 copies/mL: aOR (95% CI): 4.19 (2.07–8.49); for 10.000–99.999 copies/mL: aOR (95% CI): 2.52 (1.23–5.19)] and shorter cART duration [for <9 months: aOR (95% CI): 2.59 (1.38–4.86)]. A higher risk for VF but not for LLV was found in younger patients [for <30 years: aOR (95% CI): 2.76 (1.03–7.35); for 30–50 years: aOR (95% CI): 2.70 (1.26–5.79)], people originating from high prevalence countries [aOR (95% CI): 2.20 (1.09–4.42)] and in male injecting drug users [aOR (95% CI): 2.72 (1.38–5.34)]. CONCLUSIONS: For both VF and LLV, factors associated with adherence play a prominent role. Furthermore, performance characteristics of the diagnostic assay used for VL quantification should also be taken into consideration. Public Library of Science 2015-11-13 /pmc/articles/PMC4643888/ /pubmed/26566025 http://dx.doi.org/10.1371/journal.pone.0142923 Text en © 2015 Leierer et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Leierer, Gisela Grabmeier-Pfistershammer, Katharina Steuer, Andrea Geit, Maria Sarcletti, Mario Haas, Bernhard Kanatschnig, Manfred Rappold, Michaela Zangerle, Robert Ledergerber, Bruno Taylor, Ninon Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study |
title | Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study |
title_full | Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study |
title_fullStr | Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study |
title_full_unstemmed | Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study |
title_short | Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study |
title_sort | factors associated with low-level viraemia and virological failure: results from the austrian hiv cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643888/ https://www.ncbi.nlm.nih.gov/pubmed/26566025 http://dx.doi.org/10.1371/journal.pone.0142923 |
work_keys_str_mv | AT leierergisela factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy AT grabmeierpfistershammerkatharina factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy AT steuerandrea factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy AT geitmaria factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy AT sarclettimario factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy AT haasbernhard factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy AT kanatschnigmanfred factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy AT rappoldmichaela factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy AT zangerlerobert factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy AT ledergerberbruno factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy AT taylorninon factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy AT factorsassociatedwithlowlevelviraemiaandvirologicalfailureresultsfromtheaustrianhivcohortstudy |